Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Notes Payables: 2013-2020

Historic Notes Payables for Ocular Therapeutix (OCUL) over the last 5 years, with Dec 2020 value amounting to $8.3 million.

  • Ocular Therapeutix's Notes Payables was N/A to $2.1 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2020, which is N/A change from last year.
  • Per Ocular Therapeutix's latest filing, its Notes Payables stood at $8.3 million for FY2020, which was up 49.50% from $5.5 million recorded in FY2017.
  • Ocular Therapeutix's 5-year Notes Payables high stood at $8.3 million for FY2020, and its period low was $1.5 million during FY2016.
  • Over the past 1 years, Ocular Therapeutix's median Notes Payables value was $8.3 million (recorded in 2020), while the average stood at $8.3 million.
  • Data for Ocular Therapeutix's Notes Payables shows a peak YoY surged of 257.97% (in 2017) over the last 5 years.
  • Yearly analysis of 3 years shows Ocular Therapeutix's Notes Payables stood at $1.5 million in 2016, then skyrocketed by 257.97% to $5.5 million in 2017, then reached $8.3 million in 2020.